Photobiomodulation (PBM) Therapy on Muscle Performance in Elderly Women

NCT04241991 | Completed

• 1 other identifier: 2.893.464
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The present project aims to investigate the acute and chronic effects of laser photobiomodulation (PBM) at 808 nm on muscle performance in physically active elderly women. The hypothesis of this study is that laser PBM would improve muscle strength (i.e., MVIC and 1RM) and endurance (i.e., repetitions-to-failure, blood lactate levels), functional capacity (i.e., short physical performance battery score), and rating of perceived exertion when compared with placebo laser.

Conditions

Lasers; Resistance Training; Muscle Strength; Aged; Performance

Keywords

Photobiomodulation; Muscle function; Elderly; Resistance exercise; Balance

Outcome Measures

Primary Outcomes (6)

• Change in vastus lateralis thickness

  Muscle thickness measured by ultrasonography

  Baseline and after 10 weeks

• Change in maximal dynamic strength by 1RM

  1RM for knee extension exercise.

  Baseline and after 10 weeks

• Change in MVIC

  MVIC using a portable fixed dynamometry (i.e., compression load cell)

  Immediately after intervention (Trial 1), and baseline and after 10 weeks (Trial 2)

• Change in functional capacity

  Functional capacity measured by short physical performance battery (SPPB)

  Immediately after intervention (Trial 1).

• Change in balance

  Balance performance using a force platform.

  Baseline and after 10 weeks (Trial 2)

• Change in repetitions-to-failure

  Repetitions-to-failure test on a knee extension machine.

  Immediately after intervention (Trial 1), and baseline and after 10 weeks (Trial 2)

Secondary Outcomes (2)

• Change in lactate levels

  Immediately after repetitions-to-failure test (trial 1)

• Change in perceived exertion

  Immediately after repetitions-to-failure test (trial 1)

Study Arms (2)

Active laser

EXPERIMENTAL

Each participant will receive the application of the active laser on the rectus femoris muscle during the trials 1 (acute) and 2 (chronic).

Radiation: Active laser

Placebo laser

PLACEBO COMPARATOR

Each participant will receive the application of the placebo laser on the rectus femoris muscle during the trials 1 (acute) and 2 (chronic).

Radiation: Placebo laser

Interventions

Active laser RADIATION

Participants will receive laser irradiation on the rectus femoris muscle of both legs immediately before the test (trial 1) and training (trial 2) sessions. A researcher blinded to the treatment conditions will apply the irradiation on eight points distributed over the muscle belly, using a gallium arsenide aluminum (Ga-As-Al) laser (λ: 808 nm) equipment. The points will placed at 25, 35, 50 and 75% of the total distance between the anterior superior iliac spine and superior border of the patella, bilaterally, with 2 cm of distance between each point.

Also known as: Active laser therapy

Active laser

Placebo laser RADIATION

Participants will receive placebo irradiation on the rectus femoris muscle of both legs immediately before the test (trial 1) and training (trial 2) sessions. A researcher blinded to the treatment conditions will apply the placebo irradiation on eight points distributed over the muscle belly. The points will placed at 25, 35, 50 and 75% of the total distance between the anterior superior iliac spine and superior border of the patella, bilaterally, with 2 cm of distance between each point.

Also known as: Placebo laser therapy

Placebo laser

Eligibility Criteria

• Age: 65 Years - 80 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Older Adult (65+)

You may qualify if:

• Aged 65-80 y,
• Classified as eutrophic (i.e., body mass index ≤ 27 kg/m2), and
• Classified as physically active (i.e., performing at least 150 min/week of moderate physical activity) according to criteria of the International Physical Activity Questionnaire (IPAQ) for elderly

You may not qualify if:

• To be tobacco product users
• To make use of any ergogenic supplement within six months prior to the start of the study;
• To make use of any medication that could affect the ability to perform the physical tests;
• To have any physiological (e.g., cardiorespiratory and metabolic diseases, uncontrolled hypertension, or diabetes) or physical limitation (e.g., orthopedic or rheumatic diseases, muscular injury, fibromyalgia, or pain) that could affect the ability to perform the physical tests, or
• To be unable to understand the informed consent document and provide a detailed description of their lifestyle.

Sponsors & Collaborators

• Universidade Norte do Paraná: lead
• Universidade Estadual de Londrina: collaborator

Study Sites (1)

Universidade Norte do Paraná

Londrina, Paraná, 86.041-140, Brazil

Location

Study Officials

• Andreo Aguiar, Dr.

  North University of Paraná

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Masking Details: Participants and researchers used dark laser goggles for eye protection against irradiation, and participants were blinded by a blindfold on top of safety glasses.
• Purpose: BASIC SCIENCE
• Intervention Model: FACTORIAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: January 21, 2020
• First Posted: January 27, 2020
• Study Start: November 1, 2019
• Primary Completion: January 15, 2020
• Study Completion: January 15, 2020
• Last Updated: January 27, 2020

Record last verified: 2020-01

Data Sharing

• IPD Sharing: Will not share

Locations

BR (1)